CN106102747A - 释放no的硝基氧基‑色烯结合物 - Google Patents
释放no的硝基氧基‑色烯结合物 Download PDFInfo
- Publication number
- CN106102747A CN106102747A CN201580012500.XA CN201580012500A CN106102747A CN 106102747 A CN106102747 A CN 106102747A CN 201580012500 A CN201580012500 A CN 201580012500A CN 106102747 A CN106102747 A CN 106102747A
- Authority
- CN
- China
- Prior art keywords
- group
- methyl
- chromene
- alkyl
- nitrooxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)N(*)C(*)=O Chemical compound CC(C)N(*)C(*)=O 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927344P | 2014-01-14 | 2014-01-14 | |
| US61/927,344 | 2014-01-14 | ||
| PCT/US2015/011454 WO2015109011A1 (en) | 2014-01-14 | 2015-01-14 | No-releasing nitrooxy-chromene conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106102747A true CN106102747A (zh) | 2016-11-09 |
Family
ID=53543408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580012500.XA Pending CN106102747A (zh) | 2014-01-14 | 2015-01-14 | 释放no的硝基氧基‑色烯结合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10266511B2 (https=) |
| EP (1) | EP3094333B1 (https=) |
| CN (1) | CN106102747A (https=) |
| AU (1) | AU2015206528B2 (https=) |
| BR (1) | BR112016016386B1 (https=) |
| CA (1) | CA2936952C (https=) |
| ES (1) | ES2836374T3 (https=) |
| IL (1) | IL246794B (https=) |
| MX (1) | MX369245B (https=) |
| WO (2) | WO2015109011A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105585547A (zh) * | 2016-03-09 | 2016-05-18 | 中国科学院广州生物医药与健康研究院 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101563A1 (en) * | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
| CN103012350A (zh) * | 2012-12-07 | 2013-04-03 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021391A1 (it) | 2002-06-25 | 2003-12-29 | Nicox Sa | Nitroderivati di inibitori della cicloossigenasi-2 |
| EP1562914A1 (en) | 2002-10-22 | 2005-08-17 | Merck Frosst Canada & Co. | Nitric oxide releasing selective cyclooxygenase-2 inhibitors |
| EP1603933A2 (en) * | 2003-03-13 | 2005-12-14 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
| US7259266B2 (en) | 2003-03-31 | 2007-08-21 | Pharmacia Corporation | Benzopyran compounds useful for treating inflammatory conditions |
| US20050148627A1 (en) | 2003-03-31 | 2005-07-07 | Jeffery Carter | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| EP1692107A4 (en) * | 2003-12-10 | 2008-10-29 | Nitromed Inc | NITROGEN OXIDE-RELATED PYRUVATE COMPOUNDS, COMPOSITIONS AND USE METHOD |
| WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
| WO2009009776A2 (en) | 2007-07-12 | 2009-01-15 | Tragara Pharmaceuticals, Inc. | Patient selection and therapeutic methods using markers of prostaglandin metabolism |
-
2015
- 2015-01-14 WO PCT/US2015/011454 patent/WO2015109011A1/en not_active Ceased
- 2015-01-14 US US15/111,767 patent/US10266511B2/en active Active
- 2015-01-14 CN CN201580012500.XA patent/CN106102747A/zh active Pending
- 2015-01-14 WO PCT/US2015/011456 patent/WO2015109013A1/en not_active Ceased
- 2015-01-14 EP EP15737116.2A patent/EP3094333B1/en active Active
- 2015-01-14 ES ES15737116T patent/ES2836374T3/es active Active
- 2015-01-14 BR BR112016016386-9A patent/BR112016016386B1/pt active IP Right Grant
- 2015-01-14 AU AU2015206528A patent/AU2015206528B2/en active Active
- 2015-01-14 CA CA2936952A patent/CA2936952C/en active Active
- 2015-01-14 MX MX2016009222A patent/MX369245B/es active IP Right Grant
-
2016
- 2016-07-14 IL IL246794A patent/IL246794B/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101563A1 (en) * | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
| CN103012350A (zh) * | 2012-12-07 | 2013-04-03 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
Non-Patent Citations (1)
| Title |
|---|
| LIM DONG SUNG: "The pentafluorosulfanyl group in organic and bioorganic chemistry", 《STATE UNIVERSITY OF NEW YORK A DISSERTATION》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3094333A4 (en) | 2017-09-06 |
| MX2016009222A (es) | 2017-03-06 |
| EP3094333B1 (en) | 2020-10-14 |
| CA2936952C (en) | 2023-01-24 |
| US20160340330A1 (en) | 2016-11-24 |
| WO2015109013A1 (en) | 2015-07-23 |
| CA2936952A1 (en) | 2015-07-23 |
| ES2836374T3 (es) | 2021-06-24 |
| BR112016016386B1 (pt) | 2023-02-23 |
| BR112016016386A2 (https=) | 2017-08-08 |
| AU2015206528B2 (en) | 2019-04-18 |
| MX369245B (es) | 2019-11-01 |
| WO2015109011A1 (en) | 2015-07-23 |
| IL246794A0 (en) | 2016-08-31 |
| IL246794B (en) | 2020-04-30 |
| EP3094333A1 (en) | 2016-11-23 |
| US10266511B2 (en) | 2019-04-23 |
| AU2015206528A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106660974B (zh) | 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| CN117597341A (zh) | 磺酰胺衍生物、其制备方法及其在医药上的应用 | |
| WO2021027911A1 (zh) | 新型螺环类K-Ras G12C抑制剂 | |
| CN107375260B (zh) | 靶向癌症干细胞的新的化合物和组合物 | |
| CN107033097B (zh) | 噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| EP3210969B1 (en) | Kcnq2-5 channel activator | |
| CN110437205A (zh) | 吡啶烯基哌啶衍生物及其用途 | |
| CN111770914A (zh) | 作为神经激肽-1受体拮抗剂的化合物及其用途 | |
| JP2016516776A (ja) | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン | |
| CN107151250B (zh) | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 | |
| CN107635404A (zh) | 用于治疗疾病的mct4抑制剂 | |
| CN115594695A (zh) | 大环类化合物、其制备方法及其在医药上的应用 | |
| CA3106269A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis | |
| CN107880038A (zh) | [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途 | |
| US20150197500A1 (en) | No-releasing guanidine-chromene conjugates | |
| CN118184658A (zh) | Usp1抑制剂 | |
| WO2015109014A1 (en) | No-releasing nonoate(oxygen-bound)chromene conjugates | |
| US20200277278A1 (en) | Deuterium Atom-Substituted Indole Formamide Derivative, Preparation Method Therefor, and Medical Applications Thereof | |
| US12570668B2 (en) | Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereof | |
| CN106102747A (zh) | 释放no的硝基氧基‑色烯结合物 | |
| US9044464B2 (en) | No-releasing guanidine-coxib anti-cancer agents | |
| HK1226644A1 (en) | No-releasing nitrooxy-chromene conjugates | |
| CN117881657A (zh) | 苯基-氨磺酰基-苯甲酸衍生物作为erap1调节剂 | |
| HK40130127A (zh) | 用於治疗癌症及炎性疾病的咪唑幷[1，2-a]吡啶化合物及其制备所述化合物的方法 | |
| US20150197494A1 (en) | No-releasing nitrooxy-methylene-linked-coxib conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1226644 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |